Any revenue sharing or royalty arrangement should in theory be to Cellceutix's advantage, and more so as Brilacidin results point to efficacy, as CTIX bore the brunt of the risk and added the most value to the compound that ultimately reaches the market. Seems to me that what a Big Pharma would be providing is production expertise, sales, marketing, and distribution, all of which are valuable but have a lower expected return on capital. In layman's terms, CTIX should be earning most of the bottom line net profit. Note: this does not mean any deal should have CTIX earning > 50% of revenue; revenue is a top-line number.
Anyone with Big Pharma insight or experience who can confirm or refute this?
News 
Market Data 
Discover 
